Advanced Search

Publications > Journals > Oncology Advances > About the journal

About the journal
Aims and Scope

Oncology Advances is dedicated to improving the diagnosis and treatment of human malignancies, advancing the understanding of molecular mechanisms underlying oncogenesis, and promoting translation from bench to bedside of oncological sciences. The aim of Oncology Advances is to publish peer-reviewed, high-quality articles in all aspects of translational and clinical studies on human cancers, as well as cutting-edge preclinical and clinical research of novel cancer therapies. 

Open Access

Oncology Advances adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are subject to the same rigorous peer-review and quality control as in scholarly subscription journals.

Oncology Advances recognizes the distinct advantages of using an open access publication model to timely disseminate innovative and important research findings. Unrestricted free access to our publications is anticipated to foster intellectual discourse across geographic and disciplinary boundaries. To support the success of our open access approach, we ensure the integrity and high quality of research published in our journal by practicing a rigorous peer review process and by following strict guidelines for ethics in publication and in conduct of the scientific process.

Publication Criteria

All manuscripts submitted to Oncology Advances must meet the following criteria for publication:

  • Topics with timely relevance to the general field or specialties in basic and clinical medicine;
  • A must-have section of “hypothesis/ future direction/ prospect/ prediction” included for all research and review articles;
  • Results and findings that have not been previously published elsewhere;
  • Research performed with adherence to accepted global standards for ethics in the scientific process;
  • Ethical reporting of data to protect the rights and privacy of study participants;
  • Appropriate statistical analyses, with sufficient descriptions of all statistical methods used;
  • Conclusions supported by the data presented;
  • All funding sources and their roles cited;
  • For clinical trials, the registration number cited;
  • Manuscript written in standard American (US) English and formatted according to the journal-specific guidelines;
  • No instances of textual plagiarism, including ‘text recycling/self-plagiarism”.
Publishing Schedule
Oncology Advances currently publishes 4 issues a year, in March, June, September and December.
Indexing Services
Journal Metrics
Oncology Advances Metrics (2023)
Acceptance rate: 33.3% 
Median time from submission to first decision: 25 days 
Median time from acceptance to online publishing: 15 days
Revenue Sources

Oncology Advances adopts the open access publishing model. Revenues are generated from article processing charges (APC), permission fees, and reprints.

Oncology Advances is owned and published by Xia & He Publishing Inc.
Contact us
Editorial Office

Managing Editor: Lilia Yan
Postal Address: Room 505, Building B1, Bio-innovation Park, No. 666 High-tech Road, East Lake High-tech Development Zone, Wuhan, China


Xia & He Publishing Inc.
Tel: +1-409-420-2868 

US Office
Address: 14090 Southwest Freeway, Suite 300, Sugar Land, Texas 77478, USA

China Office
Address: Room 505, Building B1, Bio-innovation Park, No. 666 High-tech Road, East Lake High-tech Development Zone, Wuhan, China

Back to Top